Loading
Anaptysbio, Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 02 Jan 2025.
Anaptysbio, Inc: what insiders have been doing
Anaptysbio, Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 55 filings came from 12 insiders.
No insider bought on the market over the period, while 7 insiders filed 12 sales totalling €3.3M. One trade stands out by size: a sale of €612k from Schmid John P., disclosed on 1 April 2026.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 55 filings, this issuer sits above that mark. Looking back to 2021, when coverage begins, insiders filed 4 purchases and 37 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 234.6 m USD and net income at -13.2 m USD.
The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
153
Thresholds
n/a
Buy Volume
€24M
4 ops. · all time
Sell Volume
€8M
37 ops. · all time
Who traded when
BuySaleHollings Renton5 sales
John P. Schmid3 sales
Lizzul Paul F.2 sales
Loumeau Eric J2 sales
Mulroy Dennis2 sales
EcoR1 Capital, LLC1 buy
+3 other insiders
Since the insiders bought
- +195.9%Entry US$9.73 · Close at T+365 US$28.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 14,491 of 24,148 companies
45.5
score / 100
Value54
Quality38
FCF yld1.4%
Earn yld-0.9%
EV/EBITDA5.8x
ROE-115%
Gross mgn·
Net mgn-5.6%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$46.61
Analyst consensus
8 analysts1.38/5
US$60.00Target US$87.25(+87%)US$140.00
Income statement
RevenueUS$234.6M
EBITDAUS$244.1M104% margin
Net income-US$13.2M247.0% margin
Valuation
PER (forward)9.2x
P/Book130.9x
Beta0.45
Balance sheet & cash
Market capUS$1.4B
Total debtUS$14.1M
Free Cash FlowUS$19.7M
Debt / Equity2547%
Profitability & ownership
ROE-114.6%
ROA6.8%
% insiders5.6%
% institutions105.3%
Last declaration on 2 October 2026
Declarations153 total
5,000 shares@ US$18.030.0061% mcap7.1% of flowCommon StockSEC:0001187333-26-000004:0
5,000 shares@ US$49.87430.017% mcap19.5% of flowCommon StockSEC:0001187333-26-000004:1
5,000 shares@ US$49.8743100.0% of flowCommonSEC144:0001950047-26-009921
1,300 shares0Common StockSEC:0001477384-26-000013:0
10,694 shares@ US$67.17160.044% mcap63.8% of flowCommonSEC144:0001950047-26-007028
6,030 shares@ US$67.790.025% mcap36.2% of flowCommonSEC144:0001950047-26-006633
9,476 shares@ US$63.44590.037% mcap4.7% of flowCommonSEC144:0001950047-26-006580
10,000 shares@ US$60.81834.8% of flowCommonSEC144:0001950047-26-006565
850 shares@ US$60.000.4% of flowCommonSEC144:0001950047-26-006265
6,030 sharesCommon StockSEC:0001187333-26-000003:0
6,030 sharesCommon StockSEC:0001477384-26-000010:0
6,030 sharesCommon StockSEC:0001478916-26-000011:0
1,265 shares@ US$60.000.6% of flowCommonSEC144:0001950047-26-006237
20,000 shares@ US$57.65078.9% of flowCommonSEC144:0001950047-26-006156
20,000 shares@ US$55.2978.6% of flowCommonSEC144:0001950047-26-005990
35,000 shares@ US$52.821414.3% of flowCommonSEC144:0001950047-26-005960
20,000 shares@ US$52.3288.1% of flowCommonSEC144:0001950047-26-005897
20,000 shares@ US$51.61158.0% of flowCommonSEC144:0001950047-26-005838
21,987 shares@ US$50.83478.7% of flowCommonSEC144:0001950047-26-005794
22,491 shares@ US$51.29488.9% of flowCommonSEC144:0001950047-26-005723
20,000 shares@ US$51.77198.0% of flowCommonSEC144:0001950047-26-005679
20,000 shares@ US$50.86257.9% of flowCommonSEC144:0001950047-26-005601
20,000 shares@ US$51.65488.0% of flowCommonSEC144:0001950047-26-005511
522 shares@ US$57.39891.5% of flowCommon StockSEC:0001478916-26-000004:2
12,596 shares@ US$55.708734.5% of flowCommon StockSEC:0001478916-26-000004:0
25 of 153 declarations
About Anaptysbio, Inc
AnaptysBio, Inc. is a U.S.-based biotechnology company headquartered in San Diego, California, and listed on the Nasdaq Global Select Market under the ticker ANAB. For investors in French-, Belgian-, and Swiss-markets, the company is best understood as an immunology-focused biotech with a hybrid economic profile: it combines development-stage pipeline assets with royalty and collaboration economics tied to partnered programs. That mix makes AnaptysBio materially different from a classic single-asset or purely pre-revenue biotech.
The company was founded in the 2000s and built its reputation on antibody discovery and immune-pathway targeting. Over time, AnaptysBio evolved from a research-heavy organization into a more strategically segmented business model, using partnerships to monetize certain assets while continuing to advance internally controlled programs. Its shares have traded on Nasdaq since 2017, which has helped position the company within the U.S. public-market biotechnology ecosystem and given it access to a broad investor base that tends to reward scientific optionality and partnership value.
Read moreShow less
Today, the company’s most visible commercial and financial drivers are its collaborations around Jemperli with GSK and imsidolimab with Vanda, alongside an internal biopharma portfolio. On the development side, the pipeline includes rosnilimab, ANB033, and ANB101. The company has highlighted immunology indications such as ulcerative colitis, rheumatoid arthritis, celiac disease, eosinophilic esophagitis, and generalized pustular psoriasis. This is a focused but high-risk therapeutic area: the addressable market opportunity can be large, but clinical execution and differentiation are essential because immunology is crowded and highly competitive.
From a market-position standpoint, AnaptysBio competes with both large multinational pharma groups and specialized biotechnology companies pursuing inflammatory and autoimmune diseases. Its differentiation lies in a combination of scientific expertise, partnered assets that may generate royalties or milestone income, and a pipeline that could create upside if clinical data are positive. The company’s strategic objective appears to be value realization through both development success and portfolio simplification.
Recent news has been especially important. In 2026, AnaptysBio reported first-quarter results, continued to discuss a planned separation of its biopharma operations from its royalty assets, announced leadership and board changes, and authorized a $100 million share repurchase program. It also updated the market on clinical progress and setbacks: rosnilimab produced meaningful development data in rheumatoid arthritis, while its phase 2 ulcerative colitis study missed primary and secondary endpoints. These developments underscore a key point for equity investors: AnaptysBio is an event-driven Nasdaq biotech in the United States, where valuation is likely to be shaped by clinical readouts, partnership economics, and the execution of its planned corporate separation.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
